Treatment resistant depression (TRD): psychopathological profiles and pharmacological outcomes

Nicolás A. Núñez(Mayo Clinic), Gabriella Gobbi(McGill University), Maykel F. Ghabrash(McGill University Health Centre), Nancy Low(McGill University), John Tabaka(McGill University Health Centre), Pablo Cervantes(Douglas Mental Health University Institute), Eugenia Zikos, Stephen Vida(McGill University), Marie Saint-Laurent(McGill University Health Centre), T Kolivakis, Linda Booij(Centre Hospitalier Universitaire Sainte-Justine)
European Neuropsychopharmacology
October 1, 2016
10.1016/s0924-977x(16)31383-9
Cited by 0

Related Papers

Genome-wide association study identifies 30 loci associated with bipolar disorder
|Nature Genetics|2019|1.6k
Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood
|JAMA Psychiatry|2019|911
Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis
|Proceedings of the National Academy of Sciences|2005|677
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain
|Pain|2018|395
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
|Pharmacological Reviews|2018|386